Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn’s Disease: the USBIOS IG-IBD Study
Davide Giuseppe Ribaldone, Elisa Tribocco, Franco Scaldaferri, Marco Murgiano et autres
0 citationsClinical Gastroenterology and Hepatology
Anna Maria Carvalhas Gabrielli
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
10Publications signalées
59Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Inflammatory Bowel DiseaseCOVID-19 Clinical Research StudiesClostridium difficile and Clostridium perfringens researchMicroscopic ColitisCOVID-19 and healthcare impacts
Publications récentes
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)
Daniele Noviello, Walter Fries, A. Orlando, Francesco Conforti et autres
4 citationsDigestive and Liver Disease
OC.21.2 EFFICACY OF ADVANCED THERAPIES FOR THE TREATMENT OF REFRACTORY POUCHITIS IN PATIENTS WITH ILEAL-POUCH ANASTOMOSIS (IPAA): A MULTICENTRE ITALIAN REAL-LIFE EXPERIENCE
Anna Maria Carvalhas Gabrielli, Rosanna Cannatelli, Francesco Ferretti, Stefania Carmagnola et autres
0 citationsDigestive and Liver Disease
Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study
Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl et autres
2 citationsJournal of Crohn s and Colitis
Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study
Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Camilla Maria Monico, Enrico Tombetti et autres
4 citationsDigestive Diseases and Sciences
OC.06.7 LOWER INCIDENCE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH NON-GUT SELECTIVE BIOLOGIC THERAPY
Francesca Ferretti, Rosanna Cannatelli, Maria Camilla Monico, Anna Maria Carvalhas Gabrielli et autres
0 citationsDigestive and Liver Disease
Lower incidence of COVID‐19 in patients with inflammatory bowel disease treated with non‐gut selective biologic therapy
Sandro Ardizzone, Francesca Ferretti, Maria Camilla Monico, Anna Maria Carvalhas Gabrielli et autres
17 citationsJournal of Gastroenterology and Hepatology
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
Giovanni Maconi, Cristina Bosetti, Alberta De Monti, Ray Boyapati et autres
26 citationsDigestive and Liver Disease
Tocilizumab for severe COVID-19 pneumonia
Salvatore Piano, Roberto Vettor, Paolo Angeli, Gaetano Paride Arcidiacono et autres
6 citationsThe Lancet Rheumatology
Patients with Inflammatory Bowel Disease Have a Lower Risk of COVID-19: A Case-Control Study from Lombardy, Italy
Giovanni Maconi, Cristina Bosetti, Alberta De Monti, Ray Boyapati et autres
0 citationsSSRN Electronic Journal
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.